AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the new drug.

In HR-positive breast cancer, AstraZeneca continues to improve outcomes with foundational medicines Faslodex (fulvestrant) and Zoladex (goserelin) and aims to reshape the HR-positive space with ...

In HR-positive breast cancer, AstraZeneca continues to improve outcomes with foundational medicines Faslodex (fulvestrant) and Zoladex (goserelin) and aims to reshape the HR-positive space with ...

AstraZeneca has said it is considering a shift in the production of some medicines from Europe to the US in order to sidestep potential tariffs on imports introduced by the new US administration.

Chia disclosed relationships with AstraZeneca, Daiichi Sankyo, Gilead Sciences, Lilly, Novartis, and Pfizer. Clark reported no relevant relationships with industry.

The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on limiting prescription drug prices goes against a federal program.

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival (PFS) in a phase 3 breast ...

Danaher Corporation DHR recently partnered with AstraZeneca PLC AZN to develop and market novel diagnostic tools aimed at improving patient selection for precision medicine treatments. Based in ...